• Watchlist/Portfolio

    Add to watchlist:

    Only registered members can add into watchlist !

    Register here !

ValiRx focus on the treatment of cancer, specialising in epigenomic and genetic analysis. Our technologies and products however can also be applied to other fields as well, such as neurology and inflammatory diseases.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and is focused on creating a portfolio of innovative products through investment in specific development projects. We actively manage projects within this portfolio as a trading company and are not an investment vehicle.


+44 (0)203 008 4416
24 Greville Steet, London EC1N 8SS.
Super Sector:
Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
EPIC / Symbols:
*subject to change and depends on individual circumstances.

ValiRx RNS Press Releases

  • Page 1 of 54

ValiRx Articles, News, and Media Files

  • Page 1 of 11

ValiRx Related Media

  • Page 1 of 11

Broker press

  • Page 1 of 3
  • 02/02/12
    +0.13 +0.68

    Press: ValiRx rose on news its cancer screening test biomarker (NAV3) had recently received approval by the European patent office. Source - Financial Times

  • 15/12/11
    +0.02 +0.46

    Press: ValiRx rose on news that its ?gene-silencing? technology has received patent approval in Canada. It already has patents for the US,... read more

  • 16/02/11

    Press: 16.02.11: -0.52, (0.73) Press: ValiRx fell after raising GBP3.3m before expenses with a sale of new shares at 0.6p to fund the... read more

  • 14/02/11
    +1.14 +1.68

    Press: Valirx rose after announcing the UK launch of its Chlamydia SELFCheck 'over the counter' health screening product. The self diagnostic... read more

  • 25/05/10

    Press: 25.05.10: .-5, (.4) an article in the Times reports: ValiRx rose 0.07p to 0.45p after the group did a deal to sell a chlamydia... read more

Director dealings

  • Page 1 of 7
Date Director Trans Amount Type Price(p) Value (£) Holding %
23/06/14 S. Vainikka BUY 789,516 ORD 0.31 2,447 23,113,714 0.79
23/06/14 G. Desler BUY 1,595,968 ORD 0.31 4,948 12,733,921 0.43
23/06/14 S.O. Makinen BUY 1,273,387 ORD 0.31 3,947 1,273,387 0.04
23/06/14 K.J. Alexander BUY 1,612,903 ORD 0.31 5,000 8,034,843 0.27
13/07/11 S. Vainikka BUY 1,235,555 ORD 0.63 7,784 17,879,776 1.71


  • Page 1 of 7
Date Type Turnover Profit EPS (p) Dividend (p) Currency
31/12/14 Full year 0.09 -3.64 -0.08 0.00 GBX
30/06/14 Interim 0.06 -1.49 -0.05 0.00 GBX
31/12/13 Full year 0.13 -2.91 -0.15 0.00 GBX
30/06/13 Interim 0.10 -1.57 -0.09 0.00 GBX
31/12/12 Full year 0.22 -2.33 -0.17 0.00 GBX

Presentations & Company Media

Company Statement

Valirx wants to make a structural change in science, namely to engineer a scientific breakthrough into human health and wellbeing, through early detection of disease and therapeutic intervention. Research shows that there is a high demand for new personalised medicines and services that enhance patient care, achieve faster diagnoses, and substantially improve treatment outcomes cost effectively.


Valirx is a growing company with a clear business model. We reduce risk in new product development through a rigorous clinical and commercial due diligence process, selecting drug candidates and technologies with evidence-based potential to address the unmet needs of the market. We aim to maximise returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.


The Valirx management team is a mixture of entrepreneurial scientists and business professionals, all with experience in developing medical life science companies. The team is also experienced at transferring technologies and products into the commercial arena to generate revenue and grow shareholder value.

Current Operations

Our Products & Technologies

We operate through the following divisional companies:


ValiMedix is the sales and distribution division of Valirx

ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers. Of particular note is GeneICE, Valirx's technology for controlling rebellious genes, which was awarded a Eurostars grant to the value of €1.2 million to fund the development of the GeneICE products through preclinical stages in cancer treatments.

We are also pleased to report that a further late preclinical study into the development of another of our lead therapeutics, VAL201, carried out in collaboration with Oxford University, has firmly established a potentially important role for VAL201 in treating hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cell growth including breast and ovarian cancer, among others. These conditions currently have high medical needs.  Following the successful completion of this study, both Valirx and Oxford University now look forward to continuing the next stage of VAL201’s preclinical programme to support the regulatory requirements prior to entering clinical trials.




Our Business Divisions

We operate through the following divisional companies:


ValiPharma is a biopharmaceutical company focused on developing personalised medicines to bring more advanced therapeutic options for the treatment of cancer. For many years the Company has progressively exploited its proprietary epigenomic technology, which has led to the discovery of promising therapeutics that may prove in clinical trials to combat cancer safely and more effectively than currently used chemotherapeutics, which act indiscriminately, attacking the whole body and causing irreparable damage to normal cellular processes. Currently, ValiPharma has two lead drug candidates in late stage pre-clinical development for three indications – androgen independent prostate cancer, hormone refractory prostate cancer, and endometriosis.


ValiFinn’s specialist competency lies in epigenomics, a rapidly advancing field that enables pairing a prognostic and/or predictive biomarker with a targeted drug. This is a key part of personalised medicine, particularly in cancer patients. The Company is actively discovering, developing, and validating functional biomarkers with high specificity and sensitivity from its 5 families of patents and patent applications and related intellectual property. These are diagnostic markers of inhibition of signalling pathways, which are target sites for novel drugs to treat cancer, and predictive markers of disease progression


ValiMedix is the sales and distribution division of Valirx. The Company was established in 2009 to exploit the growing “well being” market through the marketing and distribution of reagent-based home screening tests under the brand SELFCheck. These tests are designed to have high sensitivity and specificity to detect levels or the presence of a range of biological markers e.g. PSA – prostate specific antigen; FSH – follicle stimulating hormone; H Pylori antibodies, that may be indicators of disease.



Mr Oliver de Giorgio-Miller - Chairman

Oliver has a wealth of experience in the management and commercial advancement of life science companies. He has worked for over 30 years with several global pharmaceutical and medical device companies including Schering AG, Hoffman la Roche, Intavent-Orthofix and Photo Therapeutics, a Cancer Research UK company and he has extensive experience advising a number of other early stage biopharmaceutical and medical device companies.


Dr Satu Vainikka - Chief Executive Officer

Satu has many years experience of the biotechnology industry, including extensive first hand experience of equity financing, business management and developing life science technology into commercial enterprises. Prior to her current role as CEO of Valirx, she was a founder, director and CEO of Cronos Therapeutics Limited.


Mr Gerry Desler - Chief Financial Officer

Gerry is a chartered accountant, who qualified in 1968 with a City firm, before becoming a partner in 1970. Between 1985 to 1990 he was the Senior Partner. During his time in the City, he has specialised in consultancy work, much of it involving funding and venture capital.


Mr Kevin Alexander - Non-Executive Director

Kevin is a qualified solicitor in England and an attorney in New York and he was a partner at major law firms in both London and the United States for over 25 years. Since leaving the law he has been involved in forming and managing various businesses, both private and public. Kevin is a director of Valirx Plc, and joined the board in September 2006. He has an MA in law from Cambridge University.


Dr George Morris - Chief Operations Officer

George has over 25 years' experience in biological and medical research, and financial services. In the past he has worked for Guy‘s hospital medical school department of medicine, King’s college and University College London. As a Research Scientist, He is an author of numerous books and articles on refereed papers, approximately 70 abstracts, short reports and posters, and an inventor of multiple patents.


Mr Seppo Mäkinen - Non-Executive Director

Seppo Mäkinen has more than 25 years of senior advisory and executive experience in board level strategic leadership and venture capital management on life science, his special expertise is on medtech / diagnostics. 

Major Shareholders

ValiRx plc is a company incorporated in the United Kingdom under the Companies Act 1985, its principle place of business is in the United Kingdom.

The Total Number of shares with nominal value 0.1p in issue is 2,921,043,530. The percentage of securities not in public hands is approximately 29%. The shareholders who hold more than 3% are as follows:

The information below was last updated on 31 March 2014.



Information taken from Valirx plc website 01/05/2014

  • Additional Information
    Share Price
    3,772.15 m
    Mkt Cap
    £8.30 m
  • Latest Stocktube

    ValiRx COO Morris highlights ‘very important year’ for company

    View full size
  • Contact Information

    Valirx Plc

    48-49 Russell Square


    WC1B 4JP



    Registered Office Address

    Valirx Plc

    24 Greville Steet


    EC1N 8SS


    Tel: +44 (0)203 0084416

    Fax: +44 (0)203 0084415

    Email: info@valirx.com


    Corporate Information

    Auditors :

    Adler Shine,

    Aston House,

    Cornwall Avenue,


    N3 1LF

    Nominated Adviser :

    Cairn Financial Advisers LLP,

    61 Cheapside,


    EC2V 6AX,



    Broker :

    Daniel Stewart & Company plc, 

    Becket House, 

    36 Old Jewry Street, 


    EC2R 8DD 



    Registrars :

    Capita Asset Services

    The Registry,

    34 Beckenham Road,


    BR3 4TU



    Bankers :

    The Royal Bank of Scotland,

    Argylle House, 

    246 Regent Street,


    W1B 3PB


    Solicitors :

    Bircham Dyson Bell,

    50 Broadway,


    SW1H 0BL,


  • ProactiveInvestors on Facebook